Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
03/07/2024 | 22:05 | Business Wire | bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:BLUE | bluebird bio Inc |
13/06/2024 | 23:00 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:BLUE | bluebird bio Inc |
04/06/2024 | 22:22 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:BLUE | bluebird bio Inc |
29/05/2024 | 13:06 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:BLUE | bluebird bio Inc |
29/05/2024 | 13:00 | Business Wire | bluebird bio Appoints O. James Sterling as Chief Financial Officer | NASDAQ:BLUE | bluebird bio Inc |
21/05/2024 | 11:45 | PR Newswire (US) | Investors in bluebird bio, Inc. Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights - BLUE | NASDAQ:BLUE | bluebird bio Inc |
15/05/2024 | 22:05 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB | NASDAQ:BLUE | bluebird bio Inc |
14/05/2024 | 11:45 | PR Newswire (US) | Class Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact The Gross Law Firm | NASDAQ:BLUE | bluebird bio Inc |
09/05/2024 | 13:00 | Business Wire | bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance | NASDAQ:BLUE | bluebird bio Inc |
07/05/2024 | 11:45 | PR Newswire (US) | The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio, Inc. Lawsuit - BLUE | NASDAQ:BLUE | bluebird bio Inc |
06/05/2024 | 13:05 | Business Wire | bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events | NASDAQ:BLUE | bluebird bio Inc |
06/05/2024 | 13:00 | Business Wire | bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy | NASDAQ:BLUE | bluebird bio Inc |
03/05/2024 | 11:45 | PR Newswire (US) | Class Action Filed Against bluebird bio, Inc. (BLUE) - May 28, 2024 Deadline to Join - Contact The Gross Law Firm | NASDAQ:BLUE | bluebird bio Inc |
26/04/2024 | 22:05 | Business Wire | bluebird bio Announces Receipt of Expected Notice from Nasdaq | NASDAQ:BLUE | bluebird bio Inc |
26/04/2024 | 11:45 | PR Newswire (US) | BLUE LAWSUIT ALERT: The Gross Law Firm Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NASDAQ:BLUE | bluebird bio Inc |
19/04/2024 | 11:45 | PR Newswire (US) | bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BLUE | NASDAQ:BLUE | bluebird bio Inc |
12/04/2024 | 11:45 | PR Newswire (US) | Shareholders that lost money on bluebird bio, Inc.(BLUE) Urged to Join Class Action - Contact The Gross Law Firm to Learn More | NASDAQ:BLUE | bluebird bio Inc |
11/04/2024 | 14:00 | Business Wire | bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:BLUE | bluebird bio Inc |
09/04/2024 | 11:45 | PR Newswire (US) | bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights - BLUE | NASDAQ:BLUE | bluebird bio Inc |
05/04/2024 | 11:45 | PR Newswire (US) | Shareholders that lost money on bluebird bio, Inc.(BLUE) should contact The Gross Law Firm about pending Class Action - BLUE | NASDAQ:BLUE | bluebird bio Inc |
26/03/2024 | 12:01 | Business Wire | bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance | NASDAQ:BLUE | bluebird bio Inc |
25/03/2024 | 21:05 | Business Wire | bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call | NASDAQ:BLUE | bluebird bio Inc |
18/03/2024 | 13:00 | Business Wire | bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital | NASDAQ:BLUE | bluebird bio Inc |
11/03/2024 | 13:00 | Business Wire | bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy | NASDAQ:BLUE | bluebird bio Inc |
14/02/2024 | 19:54 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:BLUE | bluebird bio Inc |
08/01/2024 | 22:35 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:BLUE | bluebird bio Inc |
08/01/2024 | 14:00 | Business Wire | bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook | NASDAQ:BLUE | bluebird bio Inc |
02/01/2024 | 14:00 | Business Wire | bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:BLUE | bluebird bio Inc |
20/12/2023 | 23:05 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:BLUE | bluebird bio Inc |
20/12/2023 | 03:41 | Business Wire | bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock | NASDAQ:BLUE | bluebird bio Inc |